Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3, 000 Heidelberg cases. Issue 3 (19th February 2019)

• Record Type: Journal Article
• Authors: Volckmar, Anna‐Lena; Leichsenring, Jonas; Kirchner, Martina; Christopoulos, Petros; Neumann, Olaf; Budczies, Jan; Morais de Oliveira, Cristiano Manuel; Rempel, Eugen; Buchhalter, Ivo; Brandt, Regine; Allgäuer, Michael; Talla, Suranand Babu; von Winterfeld, Moritz; Herpel, Esther; Goeppert, Benjamin; Lier, Amelie; Winter, Hauke; Brummer, Tilman; Fröhling, Stefan; Faehling, Martin; Fischer, Jürgen R.; Heußel, Claus Peter; Herth, Felix; Lasitschka, Felix; Schirmacher, Peter; Thomas, Michael; Endris, Volker; Penzel, Roland; Stenzinger, Albrecht
• Is Part Of: International journal of cancer. Volume 145:Issue 3(2019)
• Page Start: 649
• Page End: 661
• Publication Date: 2019-02-19
• Subjects: lung adenocarcinoma -- next‐generation sequencing -- drug target -- gene fusion; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.32133
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : Tyrosine kinase inhibitors currently confer the greatest survival gain for nonsmall cell lung cancer (NSCLC) patients with actionable genetic alterations. Simultaneously, the increasing number of targets and compounds poses the challenge of reliable, broad and timely molecular assays for the identification of patients likely to benefit from novel treatments. Here, we demonstrate the feasibility and clinical utility of comprehensive, NGS‐based genetic profiling for routine workup of advanced NSCLC based on the first 3, 000 patients analyzed in our department. Following automated extraction of DNA and RNA from formalin‐fixed, paraffin‐embedded tissue samples, parallel sequencing of DNA and RNA for detection of mutations and gene fusions, respectively, was performed using PCR‐based enrichment with an ion semiconductor sequencing platform. Overall, 807 patients (27%) were eligible for currently approved, EGFR‐/BRAF‐/ALK‐ and ROS1‐directed therapies, while 218 additional cases (7%) with MET, ERBB2 (HER2 ) and RET alterations could potentially benefit from experimental targeted compounds. In addition, routine capturing of comutations, e.g. TP53 (55%), KEAP1 (11%) and STK11 (11%), as well as the precise typing of fusion partners and involved exons in case of actionable translocations including ALK and ROS1, are prognostic and predictive tools currently gaining importance for further refinement of therapeutic and surveillance strategies. The reliability, low dropout rates (<5%), minimal tissue requirements, fast turnaround times (6 days on average) and lower costs of the diagnostic approach presented here compared to sequential single‐gene testing, highlight its practicability in order to support individualized decisions in routine patient care, enrollment in molecularly stratified clinical trials, as well as translational research. Abstract : What's new? Next‐generation sequencing (NGS) is an attractive option in the molecular workup of non‐small cell lung cancer (NSCLC). However, large‐scale implementation for routine diagnostics is a non‐trivial task. Here, the authors present the largest cohort of advanced NSCLC tested for mutations and translocations by combined targeted RNA‐ and DNA‐sequencing in routine diagnostics to date. The integrated approach exceeds current international guidelines and illustrates the performance and clinical impact of one‐stop shop NGS profiling. Due to amplification‐based sequencing, dropout rates are minimal and turnaround times low. By facilitating better patient stratification, such an approach can improve oncologic management and boost translational research.